| BiDil: from another vantage point. | |
| | |
MedLine Citation:
|
PMID: 16912053 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
In a recent Health Affairs Web Exclusive, Pamela Sankar and Jonathan Kahn argue against the Food and Drug Administration's approval of BiDil as a new drug for the treatment of heart failure in African Americans. Their paper questions the existence of disparities between African American and other heart-failure patients and the motivations of BiDil's developers and manufacturer. The disparities are confirmed and persistent, however, and BiDil's effectiveness is proven. If the authors' logic were to prevail, patients would be denied life-saving therapy. Continued investigation will likely narrow identification of patients who will benefit. |
| | |
Authors:
|
Gary Puckrein |
Related Documents
:
|
21619083 - Theoretical study of high-performance frontal analysis: a chromatographic method for... 22019523 - Physicochemical characterization and toxicity evaluation of steroid-based surfactants d... 10944063 - Wide variation in the number of different drugs prescribed by general practitioners. a ... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2006-08-15 |
Journal Detail:
|
Title: Health affairs (Project Hope) Volume: 25 ISSN: 1544-5208 ISO Abbreviation: Health Aff (Millwood) Publication Date: 2006 Sep-Oct |
Date Detail:
|
Created Date: 2006-09-12 Completed Date: 2007-03-07 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 8303128 Medline TA: Health Aff (Millwood) Country: United States |
Other Details:
|
Languages: eng Pagination: w368-74 Citation Subset: IM |
Affiliation:
|
National Minority Health Month Foundation in Washington, DC, USA. gpuckrein@americanvisions.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
African Americans
/
genetics* Drug Approval* Drug Combinations Drug Industry Genetic Predisposition to Disease / ethnology Heart Failure / drug therapy*, ethnology Humans Hydralazine Isosorbide Dinitrate / therapeutic use* Risk United States United States Food and Drug Administration Vasodilator Agents / therapeutic use* |
| Chemical | |
Reg. No./Substance:
|
0/Drug Combinations; 0/Vasodilator Agents; 0/isosorbide-hydralazine combination; 86-54-4/Hydralazine; 87-33-2/Isosorbide Dinitrate |
| Comments/Corrections | |
Comment In:
|
Health Aff (Millwood). 2006 Sep-Oct;25(5):w375-7
[PMID:
16912052
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Being specific about race-specific medicine.
Next Document: Circulating CD34+ cells, metabolic syndrome, and cardiovascular risk.